Natixis Autolus Therapeutics PLC Transaction History
Natixis
- $16 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding AUTL
# of Institutions
114Shares Held
160MCall Options Held
2.8KPut Options Held
89.9K-
Wellington Management Group LLP Boston, MA25.3MShares$51.7 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$41.8 Million0.24% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$33.9 Million73.83% of portfolio
-
Deep Track Capital, LP Greenwich, CT14.2MShares$29 Million1.47% of portfolio
-
Avoro Capital Advisors LLC New York, NY9.91MShares$20.2 Million0.34% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $185M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...